DBC-664 in Adult Patients With Solid Tumors
for Malignant Germ Cell Tumor
Sites in Nashville +4 more locations
Sponsor: Duboce Biopharmaceuticals, Inc.
Sex: All·Age: 18+
Code: NCT07705035·Phase 1·Recruiting·Listed Jul 15, 2026
Clinical Trials at SCRI Oncology Partners
As of August 2026, 141 paid clinical trials are recruiting at SCRI Oncology Partners, located at SCRI Oncology Partners, 335 24th Ave N #200, Nashville, TN 37203, phone (615) 329-7640 in Nashville, Tennessee. Active studies at this site cover conditions such as Breast Cancer, Colorectal Cancer and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
Newly added in Nashville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
142 clinical trials at SCRI Oncology Partners
·Clear filters· Get a weekly email when new trials open in Nashville, TN.
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
for Urothelial Cancer
Drug: PF-08634404
Sites in Nashville, Hendersonville +131 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
for Non-small Cell Lung Cancer (NSCLC)
Drug: Durvalumab
Sites in Nashville +36 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
for Advanced Non-Small Cell Lung Cancer
Drug: PF-08634404
Sites in Nashville, Mount Juliet +204 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07222566·Phase 3·Recruiting·Listed Oct 2025
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
for Carcinoma, Renal Cell
Drug: PF-08634404
Sites in Nashville, Hendersonville +107 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
for Multiple Myeloma
Sites in Nashville +29 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
for Pancreatic Cancer
Drug: daraxonrasib
Sites in Nashville +34 more locations
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for Non-small Cell Carcinoma
Sites in Nashville, Mount Juliet +216 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
for Untreated, Unresectable, or Metastatic Colorectal Cancer
Drug: Bevacizumab
Sites in Nashville +43 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Drug: Nivolumab
Sites in Nashville +33 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07221149·Phase 2, Phase 3·Recruiting·Listed Oct 2025
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
for Carcinoma, Transitional Cell
Sites in Nashville +63 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
for Multiple Myeloma
Sites in Nashville +36 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
for Breast Cancer
Sites in Nashville, Memphis +170 more locations
Sponsor: Stemline Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for Large B-cell Lymphoma
Sites in Nashville +35 more locations
Sponsor: Lyell Immunopharma, Inc.
Sex: All·Age: 18+
Code: NCT07188558·Phase 3·Recruiting·Listed Sep 2025
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Sites in Nashville, Chattanooga +126 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
for Breast Neoplasms
Sites in Nashville +33 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07060807·Phase 3·Recruiting·Listed Jul 2025
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
for Triple-Negative Breast Cancer
Sites in Nashville, Germantown +79 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06393374·Phase 3·Recruiting·Listed May 2024
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
for Breast Neoplasms
Sites in Nashville, Knoxville +58 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06966700·Phase 3·Recruiting·Listed May 2025
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
Drug: LY3537982
Sites in Nashville, Chattanooga +89 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
for Colorectal Neoplasms
Drug: Amivantamab
Sites in Nashville, Chattanooga +65 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for Lymphoma, Large B-Cell, Diffuse
Drug: Polatuzumab Vedotin
Sites in Nashville, Knoxville +69 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
for Small Cell Lung Cancer
Sites in Nashville +25 more locations
Sponsor: Puma Biotechnology, Inc.
Sex: All·Age: 18+
Code: NCT06095505·Phase 2·Recruiting·Listed Oct 2023
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Drug: Giredestrant
Sites in Nashville, Germantown +45 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for Colorectal Neoplasms
Drug: Amivantamab
Sites in Nashville +79 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
for Breast Cancer
Sites in Nashville, Knoxville +47 more locations
Sponsor: Greenwich LifeSciences, Inc.
Sex: All·Age: 18 - 100
Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for Triple Negative Breast Neoplasms
Sites in Nashville +36 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
for Advanced Cancer
Sites in Nashville, Chattanooga +36 more locations
Sponsor: Artios Pharma Ltd
Sex: All·Age: 18+
Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for Non-Small Cell Lung Cancer
Drug: Telisotuzumab Vedotin
Sites in Nashville +36 more locations
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
for Prostate Cancer Metastatic
Sites in Nashville +32 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06136624·Phase 3·Recruiting·Listed Nov 2023
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
for Carcinoma, Non-Small-Cell Lung
Drug: Adagrasib
Sites in Nashville +49 more locations
Sponsor: Mirati Therapeutics Inc.
Sex: All·Age: 18+
Code: NCT06875310·Phase 3·Recruiting·Listed Mar 2025
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
for Metastatic Colorectal Cancer
Sites in Nashville +19 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Drug: Mevrometostat
Sites in Nashville +8 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT03460977·Phase 1·Recruiting·Listed Mar 2018
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
for Non-small Cell Lung Cancer
Drug: Intismeran autogene
Sites in Nashville, Chattanooga +56 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
for Metastatic Breast Cancer
Drug: Zongertinib
Sites in Nashville, Memphis +24 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
for Melanoma
Sites in Nashville +57 more locations
Sponsor: Pfizer
Sex: All·Age: 16+
Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
for Urothelial Cancer
Sites in Nashville +32 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07106762·Phase 2, Phase 3·Recruiting·Listed Aug 2025
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for Prostate Cancer
Sites in Nashville, Memphis +47 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: Male·Age: 18+
Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
for Breast Cancer
Sites in Nashville, Germantown +100 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
for Melanoma, Cutaneous Malignant
Sites in Nashville +42 more locations
Sponsor: Immatics US, Inc.
Sex: All·Age: 18+
Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024
A Study of ASP3082 in Adults With Advanced Solid Tumors
for Solid Tumor
Sites in Nashville +24 more locations
Sponsor: Astellas Pharma Inc
Sex: All·Age: 18+
Code: NCT05382559·Phase 1·Recruiting·Listed May 2022
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
for Melanoma
Sites in Nashville +30 more locations
Sponsor: Pfizer
Sex: All·Age: 16+
Code: NCT05355701·Phase 1·Recruiting·Listed May 2022
Common conditions studied in Nashville
- Breast Cancer (43 active studies)
- Colorectal Cancer (32 active studies)
- Advanced Solid Tumor (30 active studies)
- Ovarian Cancer (28 active studies)
- Multiple Myeloma (24 active studies)
- Prostate Cancer (24 active studies)
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,355 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (43), Colorectal Cancer (32), Advanced Solid Tumor (30), Ovarian Cancer (28), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (561), Cardiovascular (90), Neurology & pain (61). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of SCRI Oncology Partners?
SCRI Oncology Partners is located at SCRI Oncology Partners, 335 24th Ave N #200, Nashville, TN 37203. Use the Google Maps link in the intro above to get directions.
How do I contact SCRI Oncology Partners?
You can reach SCRI Oncology Partners by phone at (615) 329-7640. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.
Browse more clinical trials
Other cities in Tennessee
Memphis, TN(455)Knoxville, TN(220)Chattanooga, TN(131)Germantown, TN(98)Collierville, TN(46)Jackson, TN(45)Franklin, TN(34)Kingsport, TN(33)Cordova, TN(26)Murfreesboro, TN(23)Johnson City, TN(21)Smyrna, TN(14)Tullahoma, TN(12)Hermitage, TN(9)Brentwood, TN(8)Hendersonville, TN(8)Oak Ridge, TN(8)Clarksville, TN(7)Cleveland, TN(7)Mount Juliet, TN(7)Shelbyville, TN(7)Bartlett, TN(6)Bristol, TN(6)Lebanon, TN(6)Cookeville, TN(5)Crossville, TN(5)Dickson, TN(5)Gallatin, TN(5)Hixson, TN(5)Jefferson City, TN(5)Morristown, TN(5)Powell, TN(5)Greeneville, TN(4)Goodlettsville, TN(3)Mountain Home, TN(3)Columbia, TN(2)Maryville, TN(2)Nashvile, TN(2)Tennessee City, TN(2)Winchester, TN(2)Alcoa, TN(1)Harriman, TN(1)Lenoir City, TN(1)Mephis, TN(1)Nasville, TN(1)Sevierville, TN(1)Spring Hill, TN(1)